Search

Your search keyword '"Wolpin, Brian M."' showing total 1,228 results
Start Over Author "Wolpin, Brian M."

Refine your results

more »

more »

more »

more »
1,228 results on '"Wolpin, Brian M."'

1. Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer

Author

Wasko, Urszula N., Jiang, Jingjing, Dalton, Tanner C., Curiel-Garcia, Alvaro, Edwards, A. Cole, Wang, Yingyun, Lee, Bianca, Orlen, Margo, Tian, Sha, Stalnecker, Clint A., Drizyte-Miller, Kristina, Menard, Marie, Dilly, Julien, Sastra, Stephen A., Palermo, Carmine F., Hasselluhn, Marie C., Decker-Farrell, Amanda R., Chang, Stephanie, Jiang, Lingyan, Wei, Xing, Yang, Yu C., Helland, Ciara, Courtney, Haley, Gindin, Yevgeniy, Muonio, Karl, Zhao, Ruiping, Kemp, Samantha B., Clendenin, Cynthia, Sor, Rina, Vostrejs, William P., Hibshman, Priya S., Amparo, Amber M., Hennessey, Connor, Rees, Matthew G., Ronan, Melissa M., Roth, Jennifer A., Brodbeck, Jens, Tomassoni, Lorenzo, Bakir, Basil, Socci, Nicholas D., Herring, Laura E., Barker, Natalie K., Wang, Junning, Cleary, James M., Wolpin, Brian M., Chabot, John A., Kluger, Michael D., Manji, Gulam A., Tsai, Kenneth Y., Sekulic, Miroslav, Lagana, Stephen M., Califano, Andrea, Quintana, Elsa, Wang, Zhengping, Smith, Jacqueline A. M., Holderfield, Matthew, Wildes, David, Lowe, Scott W., Badgley, Michael A., Aguirre, Andrew J., Vonderheide, Robert H., Stanger, Ben Z., Baslan, Timour, Der, Channing J., Singh, Mallika, and Olive, Kenneth P.

Published
2024
Full Text
View/download PDF

3. Clinical outcomes and ctDNA correlates for CAPOX BETR: a phase II trial of capecitabine, oxaliplatin, bevacizumab, trastuzumab in previously untreated advanced HER2+ gastroesophageal adenocarcinoma

Author

Singh, Harshabad, Lowder, Kristen E., Kapner, Kevin, Kelly, Ronan J., Zheng, Hui, McCleary, Nadine Jackson, Abrams, Thomas A., Chan, Jennifer A., Regan, Eileen M., Klempner, Samuel J., Hannigan, Alison M., Remland, Joshua, Brais, Lauren K., Andrews, Elizabeth, Yurgelun, Matthew, Cleary, James M., Rubinson, Douglas A., Ritterhouse, Lauren L., Maron, Garrett, Aguirre, Andrew J., Meyerhardt, Jeffrey A., Gardecki, Emma, Lennerz, Jochen K., Wolpin, Brian M., and Enzinger, Peter C.

Published
2024
Full Text
View/download PDF

4. Genome-wide analyses characterize shared heritability among cancers and identify novel cancer susceptibility regions

Author

Lindström, Sara, Wang, Lu, Feng, Helian, Majumdar, Arunabha, Huo, Sijia, Macdonald, James, Harrison, Tabitha, Turman, Constance, Chen, Hongjie, Mancuso, Nicholas, Bammler, Theo, Consortium, Breast Cancer Association, Gallinger, Steve, Gruber, Stephen B, Gunter, Marc J, Le Marchand, Loic, Moreno, Victor, Offit, Kenneth, Study, Genetics And Epidemiology Of Colorectal Cancer Consortium Colorectal Transdisciplinary Study Colon Cancer Family Registry, De Vivo, Immaculata, O’Mara, Tracy A, Spurdle, Amanda B, Tomlinson, Ian, Consortium, Endometrial Cancer Association, Fitzgerald, Rebecca, Gharahkhani, Puya, Gockel, Ines, Jankowski, Janusz, Macgregor, Stuart, Schumacher, Johannes, Barnholtz-Sloan, Jill, Bondy, Melissa L, Houlston, Richard S, Jenkins, Robert B, Melin, Beatrice, Wrensch, Margaret, Brennan, Paul, Christiani, David C, Johansson, Mattias, Mckay, James, Aldrich, Melinda C, Amos, Christopher I, Landi, Maria Teresa, Tardon, Adonina, Consortium, International Lung Cancer, Bishop, D Timothy, Demenais, Florence, Goldstein, Alisa M, Iles, Mark M, Kanetsky, Peter A, Law, Matthew H, Consortium, Ovarian Cancer Association, Amundadottir, Laufey T, Stolzenberg-Solomon, Rachael, Wolpin, Brian M, Consortium, Pancreatic Cancer Cohort, Klein, Alison, Petersen, Gloria, Risch, Harvey, Consortium, The PRACTICAL Consortium Pancreatic Cancer Case-Control, Chanock, Stephen J, Purdue, Mark P, Scelo, Ghislaine, Pharoah, Paul, Kar, Siddhartha, Hung, Rayjean J, Pasaniuc, Bogdan, and Kraft, Peter

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Human Genome, Genetics, Digestive Diseases, Prevention, Clinical Research, Urologic Diseases, Cancer, Rare Diseases, Aetiology, 2.1 Biological and endogenous factors, Male, Humans, Genome-Wide Association Study, Genetic Predisposition to Disease, Neoplasms, Risk Factors, Transcriptome, Polymorphism, Single Nucleotide, Breast Cancer Association Consortium, Colorectal Transdisciplinary Study (CORECT), Colon Cancer Family Registry Study (CCFR), Genetics And Epidemiology Of Colorectal Cancer Consortium, Endometrial Cancer Association Consortium, International Lung Cancer Consortium, Ovarian Cancer Association Consortium, Pancreatic Cancer Cohort Consortium, Pancreatic Cancer Case-Control Consortium (Panc4), The PRACTICAL Consortium, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

BackgroundThe shared inherited genetic contribution to risk of different cancers is not fully known. In this study, we leverage results from 12 cancer genome-wide association studies (GWAS) to quantify pairwise genome-wide genetic correlations across cancers and identify novel cancer susceptibility loci.MethodsWe collected GWAS summary statistics for 12 solid cancers based on 376 759 participants with cancer and 532 864 participants without cancer of European ancestry. The included cancer types were breast, colorectal, endometrial, esophageal, glioma, head and neck, lung, melanoma, ovarian, pancreatic, prostate, and renal cancers. We conducted cross-cancer GWAS and transcriptome-wide association studies to discover novel cancer susceptibility loci. Finally, we assessed the extent of variant-specific pleiotropy among cancers at known and newly identified cancer susceptibility loci.ResultsWe observed widespread but modest genome-wide genetic correlations across cancers. In cross-cancer GWAS and transcriptome-wide association studies, we identified 15 novel cancer susceptibility loci. Additionally, we identified multiple variants at 77 distinct loci with strong evidence of being associated with at least 2 cancer types by testing for pleiotropy at known cancer susceptibility loci.ConclusionsOverall, these results suggest that some genetic risk variants are shared among cancers, though much of cancer heritability is cancer-specific and thus tissue-specific. The increase in statistical power associated with larger sample sizes in cross-disease analysis allows for the identification of novel susceptibility regions. Future studies incorporating data on multiple cancer types are likely to identify additional regions associated with the risk of multiple cancer types.

Published
2023

5. Closed-loop automated drug infusion regulator: A clinically translatable, closed-loop drug delivery system for personalized drug dosing

Author

DeRidder, Louis B., Hare, Kyle A., Lopes, Aaron, Jenkins, Josh, Fitzgerald, Nina, MacPherson, Emmeline, Fabian, Niora, Morimoto, Josh, Chu, Jacqueline N., Kirtane, Ameya R., Madani, Wiam, Ishida, Keiko, Kuosmanen, Johannes L.P., Zecharias, Naomi, Colangelo, Christopher M., Huang, Hen-Wei, Chilekwa, Makaya, Lal, Nikhil B., Srinivasan, Shriya S., Hayward, Alison M., Wolpin, Brian M., Trumper, David, Quast, Troy, Rubinson, Douglas A., Langer, Robert, and Traverso, Giovanni

Published
2024
Full Text
View/download PDF

8. Adipose tissue and skeletal muscle wasting precede clinical diagnosis of pancreatic cancer

Author

Babic, Ana, Rosenthal, Michael H., Sundaresan, Tilak K., Khalaf, Natalia, Lee, Valerie, Brais, Lauren K., Loftus, Maureen, Caplan, Leah, Denning, Sarah, Gurung, Anamol, Harrod, Joanna, Schawkat, Khoschy, Yuan, Chen, Wang, Qiao-Li, Lee, Alice A., Biller, Leah H., Yurgelun, Matthew B., Ng, Kimmie, Nowak, Jonathan A., Aguirre, Andrew J., Bhatia, Sangeeta N., Vander Heiden, Matthew G., Van Den Eeden, Stephen K., Caan, Bette J., and Wolpin, Brian M.

Published
2023
Full Text
View/download PDF

11. A deep learning algorithm to predict risk of pancreatic cancer from disease trajectories

Author

Placido, Davide, Yuan, Bo, Hjaltelin, Jessica X., Zheng, Chunlei, Haue, Amalie D., Chmura, Piotr J., Yuan, Chen, Kim, Jihye, Umeton, Renato, Antell, Gregory, Chowdhury, Alexander, Franz, Alexandra, Brais, Lauren, Andrews, Elizabeth, Marks, Debora S., Regev, Aviv, Ayandeh, Siamack, Brophy, Mary T., Do, Nhan V., Kraft, Peter, Wolpin, Brian M., Rosenthal, Michael H., Fillmore, Nathanael R., Brunak, Søren, and Sander, Chris

Published
2023
Full Text
View/download PDF

12. Prediagnostic Inflammation and Pancreatic Cancer Survival.

Author

Yuan, Chen, Morales-Oyarvide, Vicente, Khalaf, Natalia, Perez, Kimberly, Tabung, Fred K, Ho, Gloria YF, Kooperberg, Charles, Shadyab, Aladdin H, Qi, Lihong, Kraft, Peter, Sesso, Howard D, Giovannucci, Edward L, Manson, JoAnn E, Stampfer, Meir J, Ng, Kimmie, Fuchs, Charles S, Wolpin, Brian M, and Babic, Ana

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Clinical Research, Rare Diseases, Cancer, Pancreatic Cancer, Digestive Diseases, Humans, Inflammation, Pancreatic Neoplasms, Proportional Hazards Models, Prospective Studies, Risk Factors, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

BackgroundChronic inflammation may promote initiation and progression of pancreatic cancer, but no studies have examined the association between inflammation in the period before diagnosis and pancreatic cancer survival.MethodsWe prospectively examined the association of prediagnostic plasma levels of C-reactive protein, interleukin-6, and tumor necrosis factor-α receptor 2 with survival among 492 participants from 5 large US prospective cohort studies who developed pancreatic cancer. Using an empirical dietary inflammatory pattern (EDIP) score, we evaluated whether long-term proinflammatory diets were associated with survival among 1153 patients from 2 of the 5 cohorts. Cox proportional hazards regression was used to estimate hazard ratios for death with adjustment for potential confounders. All statistical tests were 2-sided.ResultsHigher prediagnostic levels of C-reactive protein, interleukin-6, and tumor necrosis factor-α receptor 2 were individually associated with reduced survival (Ptrend = .03, .01, and .04, respectively). Compared with patients with a combined inflammatory biomarker score of 0 (all 3 marker levels below medians), those with a score of 3 (all 3 marker levels above medians) had a hazard ratio for death of 1.57 (95% confidence interval = 1.16 to 2.12; Ptrend = .003), corresponding to median overall survival times of 8 vs 5 months. Patients consuming the most proinflammatory diets (EDIP quartile 4) in the prediagnostic period had a hazard ratio for death of 1.34 (95% confidence interval = 1.13 to 1.59; Ptrend = .01), compared with those consuming the least proinflammatory diets (EDIP quartile 1).ConclusionPrediagnostic levels of inflammatory biomarkers and long-term proinflammatory diets were inversely associated with pancreatic cancer survival.

Published
2021

13. A blood-based metabolomic signature predictive of risk for pancreatic cancer

Author

Irajizad, Ehsan, Kenney, Ana, Tang, Tiffany, Vykoukal, Jody, Wu, Ranran, Murage, Eunice, Dennison, Jennifer B., Sans, Marta, Long, James P., Loftus, Maureen, Chabot, John A., Kluger, Michael D., Kastrinos, Fay, Brais, Lauren, Babic, Ana, Jajoo, Kunal, Lee, Linda S., Clancy, Thomas E., Ng, Kimmie, Bullock, Andrea, Genkinger, Jeanine M., Maitra, Anirban, Do, Kim-Anh, Yu, Bin, Wolpin, Brian M., Hanash, Sam, and Fahrmann, Johannes F.

Published
2023
Full Text
View/download PDF

15. USP9X mediates an acute adaptive response to MAPK suppression in pancreatic cancer but creates multiple actionable therapeutic vulnerabilities

Author

Perurena, Naiara, Lock, Rebecca, Davis, Rachel A., Raghavan, Srivatsan, Pilla, Natalie F., Ng, Raymond, Loi, Patrick, Guild, Caroline J., Miller, Abigail L., Sicinska, Ewa, Cleary, James M., Rubinson, Douglas A., Wolpin, Brian M., Gray, Nathanael S., Santagata, Sandro, Hahn, William C., Morton, Jennifer P., Sansom, Owen J., Aguirre, Andrew J., and Cichowski, Karen

Published
2023
Full Text
View/download PDF

16. Assessment of polygenic architecture and risk prediction based on common variants across fourteen cancers.

Author

Zhang, Yan Dora, Hurson, Amber N, Zhang, Haoyu, Choudhury, Parichoy Pal, Easton, Douglas F, Milne, Roger L, Simard, Jacques, Hall, Per, Michailidou, Kyriaki, Dennis, Joe, Schmidt, Marjanka K, Chang-Claude, Jenny, Gharahkhani, Puya, Whiteman, David, Campbell, Peter T, Hoffmeister, Michael, Jenkins, Mark, Peters, Ulrike, Hsu, Li, Gruber, Stephen B, Casey, Graham, Schmit, Stephanie L, O'Mara, Tracy A, Spurdle, Amanda B, Thompson, Deborah J, Tomlinson, Ian, De Vivo, Immaculata, Landi, Maria Teresa, Law, Matthew H, Iles, Mark M, Demenais, Florence, Kumar, Rajiv, MacGregor, Stuart, Bishop, D Timothy, Ward, Sarah V, Bondy, Melissa L, Houlston, Richard, Wiencke, John K, Melin, Beatrice, Barnholtz-Sloan, Jill, Kinnersley, Ben, Wrensch, Margaret R, Amos, Christopher I, Hung, Rayjean J, Brennan, Paul, McKay, James, Caporaso, Neil E, Berndt, Sonja I, Birmann, Brenda M, Camp, Nicola J, Kraft, Peter, Rothman, Nathaniel, Slager, Susan L, Berchuck, Andrew, Pharoah, Paul DP, Sellers, Thomas A, Gayther, Simon A, Pearce, Celeste L, Goode, Ellen L, Schildkraut, Joellen M, Moysich, Kirsten B, Amundadottir, Laufey T, Jacobs, Eric J, Klein, Alison P, Petersen, Gloria M, Risch, Harvey A, Stolzenberg-Solomon, Rachel Z, Wolpin, Brian M, Li, Donghui, Eeles, Rosalind A, Haiman, Christopher A, Kote-Jarai, Zsofia, Schumacher, Fredrick R, Al Olama, Ali Amin, Purdue, Mark P, Scelo, Ghislaine, Dalgaard, Marlene D, Greene, Mark H, Grotmol, Tom, Kanetsky, Peter A, McGlynn, Katherine A, Nathanson, Katherine L, Turnbull, Clare, Wiklund, Fredrik, Breast Cancer Association Consortium (BCAC), Barrett’s and Esophageal Adenocarcinoma Consortium (BEACON), Colon Cancer Family Registry (CCFR), Transdisciplinary Studies of Genetic Variation in Colorectal Cancer (CORECT), Endometrial Cancer Association Consortium (ECAC), Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO), Melanoma Genetics Consortium (GenoMEL), Glioma International Case-Control Study (GICC), International Lung Cancer Consortium (ILCCO), Integrative Analysis of Lung Cancer Etiology and Risk (INTEGRAL) Consortium, International Consortium of Investigators Working on Non-Hodgkin’s Lymphoma Epidemiologic Studies (InterLymph), Ovarian Cancer Association Consortium (OCAC), Oral Cancer GWAS, Pancreatic Cancer Case-Control Consortium (PanC4), Pancreatic Cancer Cohort Consortium (PanScan), and Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome (PRACTICAL)

Subjects
Breast Cancer Association Consortium, Barrett’s and Esophageal Adenocarcinoma Consortium, Colon Cancer Family Registry, Transdisciplinary Studies of Genetic Variation in Colorectal Cancer, Endometrial Cancer Association Consortium, Genetics and Epidemiology of Colorectal Cancer Consortium, Melanoma Genetics Consortium, Glioma International Case-Control Study, International Lung Cancer Consortium, Integrative Analysis of Lung Cancer Etiology and Risk (INTEGRAL) Consortium, International Consortium of Investigators Working on Non-Hodgkin’s Lymphoma Epidemiologic Studies, Ovarian Cancer Association Consortium, Oral Cancer GWAS, Pancreatic Cancer Case-Control Consortium, Pancreatic Cancer Cohort Consortium, Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome, Renal Cancer GWAS, Testicular Cancer Consortium, Animals, Humans, Neoplasms, Genetic Predisposition to Disease, Incidence, Risk Assessment, Risk Factors, Multifactorial Inheritance, Polymorphism, Single Nucleotide, Models, Genetic, Female, Male, Genome-Wide Association Study, Human Genome, Prevention, Cancer, Prostate Cancer, Genetics, Urologic Diseases, 2.1 Biological and endogenous factors
Abstract

Genome-wide association studies (GWAS) have led to the identification of hundreds of susceptibility loci across cancers, but the impact of further studies remains uncertain. Here we analyse summary-level data from GWAS of European ancestry across fourteen cancer sites to estimate the number of common susceptibility variants (polygenicity) and underlying effect-size distribution. All cancers show a high degree of polygenicity, involving at a minimum of thousands of loci. We project that sample sizes required to explain 80% of GWAS heritability vary from 60,000 cases for testicular to over 1,000,000 cases for lung cancer. The maximum relative risk achievable for subjects at the 99th risk percentile of underlying polygenic risk scores (PRS), compared to average risk, ranges from 12 for testicular to 2.5 for ovarian cancer. We show that PRS have potential for risk stratification for cancers of breast, colon and prostate, but less so for others because of modest heritability and lower incidence.

Published
2020

17. Early results of the PASS-01 trial: Pancreatic adenocarcinoma signature stratification for treatment-01.

Author

Knox, Jennifer J., primary, Jaffee, Elizabeth M., additional, O'Kane, Grainne M., additional, King, Daniel, additional, Laheru, Dan, additional, Yu, Kenneth H., additional, Perez, Kimberly, additional, Habowski, Amber N, additional, Grant, Robert C, additional, Fischer, Sandra, additional, Aguirre, Andrew, additional, Jang, Raymond Woo-Jun, additional, Devoe, Craig E., additional, O'Reilly, Eileen M., additional, Dodd, Anna, additional, Wolpin, Brian M., additional, Ye, Xiang Y, additional, Notta, Faiyaz, additional, Gallinger, Steven, additional, and Tuveson, David A., additional

Published
2024
Full Text
View/download PDF

18. Supplementary Figure 1 from RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer

Author

Singh, Harshabad, primary, Sahgal, Pranshu, primary, Kapner, Kevin, primary, Corsello, Steven M., primary, Gupta, Hersh, primary, Gujrathi, Rahul, primary, Li, Yvonne Y., primary, Cherniack, Andrew D., primary, El Alam, Raquelle, primary, Kerfoot, Joseph, primary, Andrews, Elizabeth, primary, Lee, Annette, primary, Nambiar, Chetan, primary, Hannigan, Alison M., primary, Remland, Joshua, primary, Brais, Lauren, primary, Leahy, Meghan E., primary, Rubinson, Douglas A., primary, Schlechter, Benjamin L., primary, Meyerson, Matthew, primary, Kuang, Yanan, primary, Paweletz, Cloud P., primary, Lee, Jessica K., primary, Quintanilha, Julia C.F., primary, Aguirre, Andrew J., primary, Perez, Kimberly J., primary, Huffman, Brandon M., primary, Rossi, Humberto, primary, Abrams, Thomas A., primary, Kabraji, Sheheryar, primary, Trusolino, Livio, primary, Bertotti, Andrea, primary, Sicinska, Ewa T., primary, Parikh, Aparna R., primary, Wolpin, Brian M., primary, Schrock, Alexa B., primary, Giannakis, Marios, primary, Ng, Kimmie, primary, Meyerhardt, Jeffrey A., primary, Hornick, Jason L., primary, Sethi, Nilay S., primary, and Cleary, James M., primary

Published
2024
Full Text
View/download PDF

19. Supplementary Table 1 from RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer

Author

Singh, Harshabad, primary, Sahgal, Pranshu, primary, Kapner, Kevin, primary, Corsello, Steven M., primary, Gupta, Hersh, primary, Gujrathi, Rahul, primary, Li, Yvonne Y., primary, Cherniack, Andrew D., primary, El Alam, Raquelle, primary, Kerfoot, Joseph, primary, Andrews, Elizabeth, primary, Lee, Annette, primary, Nambiar, Chetan, primary, Hannigan, Alison M., primary, Remland, Joshua, primary, Brais, Lauren, primary, Leahy, Meghan E., primary, Rubinson, Douglas A., primary, Schlechter, Benjamin L., primary, Meyerson, Matthew, primary, Kuang, Yanan, primary, Paweletz, Cloud P., primary, Lee, Jessica K., primary, Quintanilha, Julia C.F., primary, Aguirre, Andrew J., primary, Perez, Kimberly J., primary, Huffman, Brandon M., primary, Rossi, Humberto, primary, Abrams, Thomas A., primary, Kabraji, Sheheryar, primary, Trusolino, Livio, primary, Bertotti, Andrea, primary, Sicinska, Ewa T., primary, Parikh, Aparna R., primary, Wolpin, Brian M., primary, Schrock, Alexa B., primary, Giannakis, Marios, primary, Ng, Kimmie, primary, Meyerhardt, Jeffrey A., primary, Hornick, Jason L., primary, Sethi, Nilay S., primary, and Cleary, James M., primary

Published
2024
Full Text
View/download PDF

20. Supplementary Table 8 from RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer

Author

Singh, Harshabad, primary, Sahgal, Pranshu, primary, Kapner, Kevin, primary, Corsello, Steven M., primary, Gupta, Hersh, primary, Gujrathi, Rahul, primary, Li, Yvonne Y., primary, Cherniack, Andrew D., primary, El Alam, Raquelle, primary, Kerfoot, Joseph, primary, Andrews, Elizabeth, primary, Lee, Annette, primary, Nambiar, Chetan, primary, Hannigan, Alison M., primary, Remland, Joshua, primary, Brais, Lauren, primary, Leahy, Meghan E., primary, Rubinson, Douglas A., primary, Schlechter, Benjamin L., primary, Meyerson, Matthew, primary, Kuang, Yanan, primary, Paweletz, Cloud P., primary, Lee, Jessica K., primary, Quintanilha, Julia C.F., primary, Aguirre, Andrew J., primary, Perez, Kimberly J., primary, Huffman, Brandon M., primary, Rossi, Humberto, primary, Abrams, Thomas A., primary, Kabraji, Sheheryar, primary, Trusolino, Livio, primary, Bertotti, Andrea, primary, Sicinska, Ewa T., primary, Parikh, Aparna R., primary, Wolpin, Brian M., primary, Schrock, Alexa B., primary, Giannakis, Marios, primary, Ng, Kimmie, primary, Meyerhardt, Jeffrey A., primary, Hornick, Jason L., primary, Sethi, Nilay S., primary, and Cleary, James M., primary

Published
2024
Full Text
View/download PDF

21. Supplementary Table 5 from RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer

Author

Singh, Harshabad, primary, Sahgal, Pranshu, primary, Kapner, Kevin, primary, Corsello, Steven M., primary, Gupta, Hersh, primary, Gujrathi, Rahul, primary, Li, Yvonne Y., primary, Cherniack, Andrew D., primary, El Alam, Raquelle, primary, Kerfoot, Joseph, primary, Andrews, Elizabeth, primary, Lee, Annette, primary, Nambiar, Chetan, primary, Hannigan, Alison M., primary, Remland, Joshua, primary, Brais, Lauren, primary, Leahy, Meghan E., primary, Rubinson, Douglas A., primary, Schlechter, Benjamin L., primary, Meyerson, Matthew, primary, Kuang, Yanan, primary, Paweletz, Cloud P., primary, Lee, Jessica K., primary, Quintanilha, Julia C.F., primary, Aguirre, Andrew J., primary, Perez, Kimberly J., primary, Huffman, Brandon M., primary, Rossi, Humberto, primary, Abrams, Thomas A., primary, Kabraji, Sheheryar, primary, Trusolino, Livio, primary, Bertotti, Andrea, primary, Sicinska, Ewa T., primary, Parikh, Aparna R., primary, Wolpin, Brian M., primary, Schrock, Alexa B., primary, Giannakis, Marios, primary, Ng, Kimmie, primary, Meyerhardt, Jeffrey A., primary, Hornick, Jason L., primary, Sethi, Nilay S., primary, and Cleary, James M., primary

Published
2024
Full Text
View/download PDF

22. Supplementary Figure 5 from RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer

Author

Singh, Harshabad, primary, Sahgal, Pranshu, primary, Kapner, Kevin, primary, Corsello, Steven M., primary, Gupta, Hersh, primary, Gujrathi, Rahul, primary, Li, Yvonne Y., primary, Cherniack, Andrew D., primary, El Alam, Raquelle, primary, Kerfoot, Joseph, primary, Andrews, Elizabeth, primary, Lee, Annette, primary, Nambiar, Chetan, primary, Hannigan, Alison M., primary, Remland, Joshua, primary, Brais, Lauren, primary, Leahy, Meghan E., primary, Rubinson, Douglas A., primary, Schlechter, Benjamin L., primary, Meyerson, Matthew, primary, Kuang, Yanan, primary, Paweletz, Cloud P., primary, Lee, Jessica K., primary, Quintanilha, Julia C.F., primary, Aguirre, Andrew J., primary, Perez, Kimberly J., primary, Huffman, Brandon M., primary, Rossi, Humberto, primary, Abrams, Thomas A., primary, Kabraji, Sheheryar, primary, Trusolino, Livio, primary, Bertotti, Andrea, primary, Sicinska, Ewa T., primary, Parikh, Aparna R., primary, Wolpin, Brian M., primary, Schrock, Alexa B., primary, Giannakis, Marios, primary, Ng, Kimmie, primary, Meyerhardt, Jeffrey A., primary, Hornick, Jason L., primary, Sethi, Nilay S., primary, and Cleary, James M., primary

Published
2024
Full Text
View/download PDF

23. Supplementary Table 2 from RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer

Author

Singh, Harshabad, primary, Sahgal, Pranshu, primary, Kapner, Kevin, primary, Corsello, Steven M., primary, Gupta, Hersh, primary, Gujrathi, Rahul, primary, Li, Yvonne Y., primary, Cherniack, Andrew D., primary, El Alam, Raquelle, primary, Kerfoot, Joseph, primary, Andrews, Elizabeth, primary, Lee, Annette, primary, Nambiar, Chetan, primary, Hannigan, Alison M., primary, Remland, Joshua, primary, Brais, Lauren, primary, Leahy, Meghan E., primary, Rubinson, Douglas A., primary, Schlechter, Benjamin L., primary, Meyerson, Matthew, primary, Kuang, Yanan, primary, Paweletz, Cloud P., primary, Lee, Jessica K., primary, Quintanilha, Julia C.F., primary, Aguirre, Andrew J., primary, Perez, Kimberly J., primary, Huffman, Brandon M., primary, Rossi, Humberto, primary, Abrams, Thomas A., primary, Kabraji, Sheheryar, primary, Trusolino, Livio, primary, Bertotti, Andrea, primary, Sicinska, Ewa T., primary, Parikh, Aparna R., primary, Wolpin, Brian M., primary, Schrock, Alexa B., primary, Giannakis, Marios, primary, Ng, Kimmie, primary, Meyerhardt, Jeffrey A., primary, Hornick, Jason L., primary, Sethi, Nilay S., primary, and Cleary, James M., primary

Published
2024
Full Text
View/download PDF

24. Supplementary Table 9 from RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer

Author

Singh, Harshabad, primary, Sahgal, Pranshu, primary, Kapner, Kevin, primary, Corsello, Steven M., primary, Gupta, Hersh, primary, Gujrathi, Rahul, primary, Li, Yvonne Y., primary, Cherniack, Andrew D., primary, El Alam, Raquelle, primary, Kerfoot, Joseph, primary, Andrews, Elizabeth, primary, Lee, Annette, primary, Nambiar, Chetan, primary, Hannigan, Alison M., primary, Remland, Joshua, primary, Brais, Lauren, primary, Leahy, Meghan E., primary, Rubinson, Douglas A., primary, Schlechter, Benjamin L., primary, Meyerson, Matthew, primary, Kuang, Yanan, primary, Paweletz, Cloud P., primary, Lee, Jessica K., primary, Quintanilha, Julia C.F., primary, Aguirre, Andrew J., primary, Perez, Kimberly J., primary, Huffman, Brandon M., primary, Rossi, Humberto, primary, Abrams, Thomas A., primary, Kabraji, Sheheryar, primary, Trusolino, Livio, primary, Bertotti, Andrea, primary, Sicinska, Ewa T., primary, Parikh, Aparna R., primary, Wolpin, Brian M., primary, Schrock, Alexa B., primary, Giannakis, Marios, primary, Ng, Kimmie, primary, Meyerhardt, Jeffrey A., primary, Hornick, Jason L., primary, Sethi, Nilay S., primary, and Cleary, James M., primary

Published
2024
Full Text
View/download PDF

25. Supplementary Table 7 from RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer

Author

Singh, Harshabad, primary, Sahgal, Pranshu, primary, Kapner, Kevin, primary, Corsello, Steven M., primary, Gupta, Hersh, primary, Gujrathi, Rahul, primary, Li, Yvonne Y., primary, Cherniack, Andrew D., primary, El Alam, Raquelle, primary, Kerfoot, Joseph, primary, Andrews, Elizabeth, primary, Lee, Annette, primary, Nambiar, Chetan, primary, Hannigan, Alison M., primary, Remland, Joshua, primary, Brais, Lauren, primary, Leahy, Meghan E., primary, Rubinson, Douglas A., primary, Schlechter, Benjamin L., primary, Meyerson, Matthew, primary, Kuang, Yanan, primary, Paweletz, Cloud P., primary, Lee, Jessica K., primary, Quintanilha, Julia C.F., primary, Aguirre, Andrew J., primary, Perez, Kimberly J., primary, Huffman, Brandon M., primary, Rossi, Humberto, primary, Abrams, Thomas A., primary, Kabraji, Sheheryar, primary, Trusolino, Livio, primary, Bertotti, Andrea, primary, Sicinska, Ewa T., primary, Parikh, Aparna R., primary, Wolpin, Brian M., primary, Schrock, Alexa B., primary, Giannakis, Marios, primary, Ng, Kimmie, primary, Meyerhardt, Jeffrey A., primary, Hornick, Jason L., primary, Sethi, Nilay S., primary, and Cleary, James M., primary

Published
2024
Full Text
View/download PDF

26. Supplementary Figure 6 from RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer

Author

Singh, Harshabad, primary, Sahgal, Pranshu, primary, Kapner, Kevin, primary, Corsello, Steven M., primary, Gupta, Hersh, primary, Gujrathi, Rahul, primary, Li, Yvonne Y., primary, Cherniack, Andrew D., primary, El Alam, Raquelle, primary, Kerfoot, Joseph, primary, Andrews, Elizabeth, primary, Lee, Annette, primary, Nambiar, Chetan, primary, Hannigan, Alison M., primary, Remland, Joshua, primary, Brais, Lauren, primary, Leahy, Meghan E., primary, Rubinson, Douglas A., primary, Schlechter, Benjamin L., primary, Meyerson, Matthew, primary, Kuang, Yanan, primary, Paweletz, Cloud P., primary, Lee, Jessica K., primary, Quintanilha, Julia C.F., primary, Aguirre, Andrew J., primary, Perez, Kimberly J., primary, Huffman, Brandon M., primary, Rossi, Humberto, primary, Abrams, Thomas A., primary, Kabraji, Sheheryar, primary, Trusolino, Livio, primary, Bertotti, Andrea, primary, Sicinska, Ewa T., primary, Parikh, Aparna R., primary, Wolpin, Brian M., primary, Schrock, Alexa B., primary, Giannakis, Marios, primary, Ng, Kimmie, primary, Meyerhardt, Jeffrey A., primary, Hornick, Jason L., primary, Sethi, Nilay S., primary, and Cleary, James M., primary

Published
2024
Full Text
View/download PDF

27. Supplementary Table 3 from RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer

Author

Singh, Harshabad, primary, Sahgal, Pranshu, primary, Kapner, Kevin, primary, Corsello, Steven M., primary, Gupta, Hersh, primary, Gujrathi, Rahul, primary, Li, Yvonne Y., primary, Cherniack, Andrew D., primary, El Alam, Raquelle, primary, Kerfoot, Joseph, primary, Andrews, Elizabeth, primary, Lee, Annette, primary, Nambiar, Chetan, primary, Hannigan, Alison M., primary, Remland, Joshua, primary, Brais, Lauren, primary, Leahy, Meghan E., primary, Rubinson, Douglas A., primary, Schlechter, Benjamin L., primary, Meyerson, Matthew, primary, Kuang, Yanan, primary, Paweletz, Cloud P., primary, Lee, Jessica K., primary, Quintanilha, Julia C.F., primary, Aguirre, Andrew J., primary, Perez, Kimberly J., primary, Huffman, Brandon M., primary, Rossi, Humberto, primary, Abrams, Thomas A., primary, Kabraji, Sheheryar, primary, Trusolino, Livio, primary, Bertotti, Andrea, primary, Sicinska, Ewa T., primary, Parikh, Aparna R., primary, Wolpin, Brian M., primary, Schrock, Alexa B., primary, Giannakis, Marios, primary, Ng, Kimmie, primary, Meyerhardt, Jeffrey A., primary, Hornick, Jason L., primary, Sethi, Nilay S., primary, and Cleary, James M., primary

Published
2024
Full Text
View/download PDF

28. Supplementary Methods 1 from RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer

Author

Singh, Harshabad, primary, Sahgal, Pranshu, primary, Kapner, Kevin, primary, Corsello, Steven M., primary, Gupta, Hersh, primary, Gujrathi, Rahul, primary, Li, Yvonne Y., primary, Cherniack, Andrew D., primary, El Alam, Raquelle, primary, Kerfoot, Joseph, primary, Andrews, Elizabeth, primary, Lee, Annette, primary, Nambiar, Chetan, primary, Hannigan, Alison M., primary, Remland, Joshua, primary, Brais, Lauren, primary, Leahy, Meghan E., primary, Rubinson, Douglas A., primary, Schlechter, Benjamin L., primary, Meyerson, Matthew, primary, Kuang, Yanan, primary, Paweletz, Cloud P., primary, Lee, Jessica K., primary, Quintanilha, Julia C.F., primary, Aguirre, Andrew J., primary, Perez, Kimberly J., primary, Huffman, Brandon M., primary, Rossi, Humberto, primary, Abrams, Thomas A., primary, Kabraji, Sheheryar, primary, Trusolino, Livio, primary, Bertotti, Andrea, primary, Sicinska, Ewa T., primary, Parikh, Aparna R., primary, Wolpin, Brian M., primary, Schrock, Alexa B., primary, Giannakis, Marios, primary, Ng, Kimmie, primary, Meyerhardt, Jeffrey A., primary, Hornick, Jason L., primary, Sethi, Nilay S., primary, and Cleary, James M., primary

Published
2024
Full Text
View/download PDF

29. Supplementary Figure 3 from RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer

Author

Singh, Harshabad, primary, Sahgal, Pranshu, primary, Kapner, Kevin, primary, Corsello, Steven M., primary, Gupta, Hersh, primary, Gujrathi, Rahul, primary, Li, Yvonne Y., primary, Cherniack, Andrew D., primary, El Alam, Raquelle, primary, Kerfoot, Joseph, primary, Andrews, Elizabeth, primary, Lee, Annette, primary, Nambiar, Chetan, primary, Hannigan, Alison M., primary, Remland, Joshua, primary, Brais, Lauren, primary, Leahy, Meghan E., primary, Rubinson, Douglas A., primary, Schlechter, Benjamin L., primary, Meyerson, Matthew, primary, Kuang, Yanan, primary, Paweletz, Cloud P., primary, Lee, Jessica K., primary, Quintanilha, Julia C.F., primary, Aguirre, Andrew J., primary, Perez, Kimberly J., primary, Huffman, Brandon M., primary, Rossi, Humberto, primary, Abrams, Thomas A., primary, Kabraji, Sheheryar, primary, Trusolino, Livio, primary, Bertotti, Andrea, primary, Sicinska, Ewa T., primary, Parikh, Aparna R., primary, Wolpin, Brian M., primary, Schrock, Alexa B., primary, Giannakis, Marios, primary, Ng, Kimmie, primary, Meyerhardt, Jeffrey A., primary, Hornick, Jason L., primary, Sethi, Nilay S., primary, and Cleary, James M., primary

Published
2024
Full Text
View/download PDF

30. Supplementary Table 6 from RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer

Author

Singh, Harshabad, primary, Sahgal, Pranshu, primary, Kapner, Kevin, primary, Corsello, Steven M., primary, Gupta, Hersh, primary, Gujrathi, Rahul, primary, Li, Yvonne Y., primary, Cherniack, Andrew D., primary, El Alam, Raquelle, primary, Kerfoot, Joseph, primary, Andrews, Elizabeth, primary, Lee, Annette, primary, Nambiar, Chetan, primary, Hannigan, Alison M., primary, Remland, Joshua, primary, Brais, Lauren, primary, Leahy, Meghan E., primary, Rubinson, Douglas A., primary, Schlechter, Benjamin L., primary, Meyerson, Matthew, primary, Kuang, Yanan, primary, Paweletz, Cloud P., primary, Lee, Jessica K., primary, Quintanilha, Julia C.F., primary, Aguirre, Andrew J., primary, Perez, Kimberly J., primary, Huffman, Brandon M., primary, Rossi, Humberto, primary, Abrams, Thomas A., primary, Kabraji, Sheheryar, primary, Trusolino, Livio, primary, Bertotti, Andrea, primary, Sicinska, Ewa T., primary, Parikh, Aparna R., primary, Wolpin, Brian M., primary, Schrock, Alexa B., primary, Giannakis, Marios, primary, Ng, Kimmie, primary, Meyerhardt, Jeffrey A., primary, Hornick, Jason L., primary, Sethi, Nilay S., primary, and Cleary, James M., primary

Published
2024
Full Text
View/download PDF

31. Supplementary Figure 2 from RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer

Author

Singh, Harshabad, primary, Sahgal, Pranshu, primary, Kapner, Kevin, primary, Corsello, Steven M., primary, Gupta, Hersh, primary, Gujrathi, Rahul, primary, Li, Yvonne Y., primary, Cherniack, Andrew D., primary, El Alam, Raquelle, primary, Kerfoot, Joseph, primary, Andrews, Elizabeth, primary, Lee, Annette, primary, Nambiar, Chetan, primary, Hannigan, Alison M., primary, Remland, Joshua, primary, Brais, Lauren, primary, Leahy, Meghan E., primary, Rubinson, Douglas A., primary, Schlechter, Benjamin L., primary, Meyerson, Matthew, primary, Kuang, Yanan, primary, Paweletz, Cloud P., primary, Lee, Jessica K., primary, Quintanilha, Julia C.F., primary, Aguirre, Andrew J., primary, Perez, Kimberly J., primary, Huffman, Brandon M., primary, Rossi, Humberto, primary, Abrams, Thomas A., primary, Kabraji, Sheheryar, primary, Trusolino, Livio, primary, Bertotti, Andrea, primary, Sicinska, Ewa T., primary, Parikh, Aparna R., primary, Wolpin, Brian M., primary, Schrock, Alexa B., primary, Giannakis, Marios, primary, Ng, Kimmie, primary, Meyerhardt, Jeffrey A., primary, Hornick, Jason L., primary, Sethi, Nilay S., primary, and Cleary, James M., primary

Published
2024
Full Text
View/download PDF

32. Supplementary Table 4 from RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer

Author

Singh, Harshabad, primary, Sahgal, Pranshu, primary, Kapner, Kevin, primary, Corsello, Steven M., primary, Gupta, Hersh, primary, Gujrathi, Rahul, primary, Li, Yvonne Y., primary, Cherniack, Andrew D., primary, El Alam, Raquelle, primary, Kerfoot, Joseph, primary, Andrews, Elizabeth, primary, Lee, Annette, primary, Nambiar, Chetan, primary, Hannigan, Alison M., primary, Remland, Joshua, primary, Brais, Lauren, primary, Leahy, Meghan E., primary, Rubinson, Douglas A., primary, Schlechter, Benjamin L., primary, Meyerson, Matthew, primary, Kuang, Yanan, primary, Paweletz, Cloud P., primary, Lee, Jessica K., primary, Quintanilha, Julia C.F., primary, Aguirre, Andrew J., primary, Perez, Kimberly J., primary, Huffman, Brandon M., primary, Rossi, Humberto, primary, Abrams, Thomas A., primary, Kabraji, Sheheryar, primary, Trusolino, Livio, primary, Bertotti, Andrea, primary, Sicinska, Ewa T., primary, Parikh, Aparna R., primary, Wolpin, Brian M., primary, Schrock, Alexa B., primary, Giannakis, Marios, primary, Ng, Kimmie, primary, Meyerhardt, Jeffrey A., primary, Hornick, Jason L., primary, Sethi, Nilay S., primary, and Cleary, James M., primary

Published
2024
Full Text
View/download PDF

33. Supplementary Figure 4 from RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer

Author

Singh, Harshabad, primary, Sahgal, Pranshu, primary, Kapner, Kevin, primary, Corsello, Steven M., primary, Gupta, Hersh, primary, Gujrathi, Rahul, primary, Li, Yvonne Y., primary, Cherniack, Andrew D., primary, El Alam, Raquelle, primary, Kerfoot, Joseph, primary, Andrews, Elizabeth, primary, Lee, Annette, primary, Nambiar, Chetan, primary, Hannigan, Alison M., primary, Remland, Joshua, primary, Brais, Lauren, primary, Leahy, Meghan E., primary, Rubinson, Douglas A., primary, Schlechter, Benjamin L., primary, Meyerson, Matthew, primary, Kuang, Yanan, primary, Paweletz, Cloud P., primary, Lee, Jessica K., primary, Quintanilha, Julia C.F., primary, Aguirre, Andrew J., primary, Perez, Kimberly J., primary, Huffman, Brandon M., primary, Rossi, Humberto, primary, Abrams, Thomas A., primary, Kabraji, Sheheryar, primary, Trusolino, Livio, primary, Bertotti, Andrea, primary, Sicinska, Ewa T., primary, Parikh, Aparna R., primary, Wolpin, Brian M., primary, Schrock, Alexa B., primary, Giannakis, Marios, primary, Ng, Kimmie, primary, Meyerhardt, Jeffrey A., primary, Hornick, Jason L., primary, Sethi, Nilay S., primary, and Cleary, James M., primary

Published
2024
Full Text
View/download PDF

34. Data from RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer

Author

Singh, Harshabad, primary, Sahgal, Pranshu, primary, Kapner, Kevin, primary, Corsello, Steven M., primary, Gupta, Hersh, primary, Gujrathi, Rahul, primary, Li, Yvonne Y., primary, Cherniack, Andrew D., primary, El Alam, Raquelle, primary, Kerfoot, Joseph, primary, Andrews, Elizabeth, primary, Lee, Annette, primary, Nambiar, Chetan, primary, Hannigan, Alison M., primary, Remland, Joshua, primary, Brais, Lauren, primary, Leahy, Meghan E., primary, Rubinson, Douglas A., primary, Schlechter, Benjamin L., primary, Meyerson, Matthew, primary, Kuang, Yanan, primary, Paweletz, Cloud P., primary, Lee, Jessica K., primary, Quintanilha, Julia C.F., primary, Aguirre, Andrew J., primary, Perez, Kimberly J., primary, Huffman, Brandon M., primary, Rossi, Humberto, primary, Abrams, Thomas A., primary, Kabraji, Sheheryar, primary, Trusolino, Livio, primary, Bertotti, Andrea, primary, Sicinska, Ewa T., primary, Parikh, Aparna R., primary, Wolpin, Brian M., primary, Schrock, Alexa B., primary, Giannakis, Marios, primary, Ng, Kimmie, primary, Meyerhardt, Jeffrey A., primary, Hornick, Jason L., primary, Sethi, Nilay S., primary, and Cleary, James M., primary

Published
2024
Full Text
View/download PDF

35. Helicobacter pylori Seropositivity, ABO Blood Type, and Pancreatic Cancer Risk from 5 Prospective Cohorts

Author

Lee, Alice A., Wang, Qiao-Li, Kim, Jihye, Babic, Ana, Zhang, Xuehong, Perez, Kimberly, Ng, Kimmie, Nowak, Jonathan, Rifazzzzzzzzgi, Nader, Sesso, Howard D., Buring, Julie E., Anderson, Garnet L., Wactawski-Wende, Jean, Wallace, Robert, Manson, JoAnn E., Giovannucci, Edward L., Stampfer, Meir J., Kraft, Peter, Fuchs, Charles S., Yuan, Chen, and Wolpin, Brian M.

Published
2023
Full Text
View/download PDF

38. Low glycaemic diets alter lipid metabolism to influence tumour growth

Author

Lien, Evan C., Westermark, Anna M., Zhang, Yin, Yuan, Chen, Li, Zhaoqi, Lau, Allison N., Sapp, Kiera M., Wolpin, Brian M., and Vander Heiden, Matthew G.

Subjects
Tumors -- Diet therapy, Dextrose -- Physiological aspects, Glucose -- Physiological aspects, Lipid metabolism -- Health aspects, Environmental issues, Science and technology, Zoology and wildlife conservation
Abstract

Dietary interventions can change metabolite levels in the tumour microenvironment, which might then affect cancer cell metabolism to alter tumour growth.sup.1-5. Although caloric restriction (CR) and a ketogenic diet (KD) are often thought to limit tumour progression by lowering blood glucose and insulin levels.sup.6-8, we found that only CR inhibits the growth of select tumour allografts in mice, suggesting that other mechanisms contribute to tumour growth inhibition. A change in nutrient availability observed with CR, but not with KD, is lower lipid levels in the plasma and tumours. Upregulation of stearoyl-CoA desaturase (SCD), which synthesises monounsaturated fatty acids, is required for cancer cells to proliferate in a lipid-depleted environment, and CR also impairs tumour SCD activity to cause an imbalance between unsaturated and saturated fatty acids to slow tumour growth. Enforcing cancer cell SCD expression or raising circulating lipid levels through a higher-fat CR diet confers resistance to the effects of CR. By contrast, although KD also impairs tumour SCD activity, KD-driven increases in lipid availability maintain the unsaturated to saturated fatty acid ratios in tumours, and changing the KD fat composition to increase tumour saturated fatty acid levels cooperates with decreased tumour SCD activity to slow tumour growth. These data suggest that diet-induced mismatches between tumour fatty acid desaturation activity and the availability of specific fatty acid species determine whether low glycaemic diets impair tumour growth. Lien et al. show that low glycemic diets can reduce tumour growth by deregulating lipid metabolism., Author(s): Evan C. Lien [sup.1] , Anna M. Westermark [sup.1] , Yin Zhang [sup.2] [sup.3] , Chen Yuan [sup.2] , Zhaoqi Li [sup.1] [sup.4] , Allison N. Lau [sup.1] , [...]

Published
2021
Full Text
View/download PDF

39. Programmatic Precision Oncology Decision Support for Patients With Gastrointestinal Cancer

Author

Keller, Rachel B., Mazor, Tali, Sholl, Lynette, Aguirre, Andrew J., Singh, Harshabad, Sethi, Nilay, Bass, Adam, Nagaraja, Ankur K., Brais, Lauren K., Hill, Emma, Hennessey, Connor, Cusick, Margaret, Del Vecchio Fitz, Catherine, Zwiesler, Zachary, Siegel, Ethan, Ovalle, Andrea, Trukhanov, Pavel, Hansel, Jason, Shapiro, Geoffrey I., Abrams, Thomas A., Biller, Leah H., Chan, Jennifer A., Cleary, James M., Corsello, Steven M., Enzinger, Andrea C., Enzinger, Peter C., Mayer, Robert J., McCleary, Nadine J., Meyerhardt, Jeffrey A., Ng, Kimmie, Patel, Anuj K., Perez, Kimberley J., Rahma, Osama E., Rubinson, Douglas A., Wisch, Jeffrey S., Yurgelun, Matthew B., Hassett, Michael J., MacConaill, Laura, Schrag, Deborah, Cerami, Ethan, Wolpin, Brian M., Nowak, Jonathan A., and Giannakis, Marios

Published
2023
Full Text
View/download PDF

40. Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer.

Author

Tiriac, Hervé, Belleau, Pascal, Engle, Dannielle D, Plenker, Dennis, Deschênes, Astrid, Somerville, Tim DD, Froeling, Fieke EM, Burkhart, Richard A, Denroche, Robert E, Jang, Gun-Ho, Miyabayashi, Koji, Young, C Megan, Patel, Hardik, Ma, Michelle, LaComb, Joseph F, Palmaira, Randze Lerie D, Javed, Ammar A, Huynh, Jasmine C, Johnson, Molly, Arora, Kanika, Robine, Nicolas, Shah, Minita, Sanghvi, Rashesh, Goetz, Austin B, Lowder, Cinthya Y, Martello, Laura, Driehuis, Else, LeComte, Nicolas, Askan, Gokce, Iacobuzio-Donahue, Christine A, Clevers, Hans, Wood, Laura D, Hruban, Ralph H, Thompson, Elizabeth, Aguirre, Andrew J, Wolpin, Brian M, Sasson, Aaron, Kim, Joseph, Wu, Maoxin, Bucobo, Juan Carlos, Allen, Peter, Sejpal, Divyesh V, Nealon, William, Sullivan, James D, Winter, Jordan M, Gimotty, Phyllis A, Grem, Jean L, DiMaio, Dominick J, Buscaglia, Jonathan M, Grandgenett, Paul M, Brody, Jonathan R, Hollingsworth, Michael A, O'Kane, Grainne M, Notta, Faiyaz, Kim, Edward, Crawford, James M, Devoe, Craig, Ocean, Allyson, Wolfgang, Christopher L, Yu, Kenneth H, Li, Ellen, Vakoc, Christopher R, Hubert, Benjamin, Fischer, Sandra E, Wilson, Julie M, Moffitt, Richard, Knox, Jennifer, Krasnitz, Alexander, Gallinger, Steven, and Tuveson, David A

Subjects
Organoids, Tumor Cells, Cultured, Humans, Pancreatic Neoplasms, Antineoplastic Agents, Drug Screening Assays, Antitumor, Prospective Studies, Gene Expression Profiling, Sequence Analysis, RNA, Gene Expression Regulation, Neoplastic, Drug Resistance, Neoplasm, Gene Regulatory Networks, Molecular Targeted Therapy, Standard of Care, Precision Medicine, Genetics, Pancreatic Cancer, Rare Diseases, Digestive Diseases, Orphan Drug, Cancer, Detection, screening and diagnosis, Development of treatments and therapeutic interventions, 4.1 Discovery and preclinical testing of markers and technologies, 5.1 Pharmaceuticals, Good Health and Well Being, Oncology and Carcinogenesis
Abstract

Pancreatic cancer is the most lethal common solid malignancy. Systemic therapies are often ineffective, and predictive biomarkers to guide treatment are urgently needed. We generated a pancreatic cancer patient-derived organoid (PDO) library that recapitulates the mutational spectrum and transcriptional subtypes of primary pancreatic cancer. New driver oncogenes were nominated and transcriptomic analyses revealed unique clusters. PDOs exhibited heterogeneous responses to standard-of-care chemotherapeutics and investigational agents. In a case study manner, we found that PDO therapeutic profiles paralleled patient outcomes and that PDOs enabled longitudinal assessment of chemosensitivity and evaluation of synchronous metastases. We derived organoid-based gene expression signatures of chemosensitivity that predicted improved responses for many patients to chemotherapy in both the adjuvant and advanced disease settings. Finally, we nominated alternative treatment strategies for chemorefractory PDOs using targeted agent therapeutic profiling. We propose that combined molecular and therapeutic profiling of PDOs may predict clinical response and enable prospective therapeutic selection.Significance: New approaches to prioritize treatment strategies are urgently needed to improve survival and quality of life for patients with pancreatic cancer. Combined genomic, transcriptomic, and therapeutic profiling of PDOs can identify molecular and functional subtypes of pancreatic cancer, predict therapeutic responses, and facilitate precision medicine for patients with pancreatic cancer. Cancer Discov; 8(9); 1112-29. ©2018 AACR.See related commentary by Collisson, p. 1062This article is highlighted in the In This Issue feature, p. 1047.

Published
2018

41. Machine learning links T-cell function and spatial localization to neoadjuvant immunotherapy and clinical outcome in pancreatic cancer

Author

Blise, Katie E., primary, Sivagnanam, Shamilene, additional, Betts, Courtney B., additional, Betre, Konjit, additional, Kirchberger, Nell, additional, Tate, Benjamin J., additional, Furth, Emma E., additional, Dias Costa, Andressa, additional, Nowak, Jonathan A., additional, Wolpin, Brian M., additional, Vonderheide, Robert H., additional, Goecks, Jeremy, additional, Coussens, Lisa M., additional, and Byrne, Katelyn T., additional

Published
2024
Full Text
View/download PDF

42. Data from Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer

Author

Byrne, Katelyn T., primary, Betts, Courtney B., primary, Mick, Rosemarie, primary, Sivagnanam, Shamilene, primary, Bajor, David L., primary, Laheru, Daniel A., primary, Chiorean, E. Gabriela, primary, O'Hara, Mark H., primary, Liudahl, Shannon M., primary, Newcomb, Craig, primary, Alanio, Cécile, primary, Ferreira, Ana P., primary, Park, Byung S., primary, Ohtani, Takuya, primary, Huffman, Austin P., primary, Väyrynen, Sara A., primary, Dias Costa, Andressa, primary, Kaiser, Judith C., primary, Lacroix, Andreanne M., primary, Redlinger, Colleen, primary, Stern, Martin, primary, Nowak, Jonathan A., primary, Wherry, E. John, primary, Cheever, Martin A., primary, Wolpin, Brian M., primary, Furth, Emma E., primary, Jaffee, Elizabeth M., primary, Coussens, Lisa M., primary, and Vonderheide, Robert H., primary

Published
2024
Full Text
View/download PDF

43. Supplementary Table 2 from Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer

Author

Byrne, Katelyn T., primary, Betts, Courtney B., primary, Mick, Rosemarie, primary, Sivagnanam, Shamilene, primary, Bajor, David L., primary, Laheru, Daniel A., primary, Chiorean, E. Gabriela, primary, O'Hara, Mark H., primary, Liudahl, Shannon M., primary, Newcomb, Craig, primary, Alanio, Cécile, primary, Ferreira, Ana P., primary, Park, Byung S., primary, Ohtani, Takuya, primary, Huffman, Austin P., primary, Väyrynen, Sara A., primary, Dias Costa, Andressa, primary, Kaiser, Judith C., primary, Lacroix, Andreanne M., primary, Redlinger, Colleen, primary, Stern, Martin, primary, Nowak, Jonathan A., primary, Wherry, E. John, primary, Cheever, Martin A., primary, Wolpin, Brian M., primary, Furth, Emma E., primary, Jaffee, Elizabeth M., primary, Coussens, Lisa M., primary, and Vonderheide, Robert H., primary

Published
2024
Full Text
View/download PDF

44. Supplementary Data 1 from PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with Pancreatic Cancer

Author

Ali, Lestat R., primary, Lenehan, Patrick J., primary, Cardot-Ruffino, Victoire, primary, Dias Costa, Andressa, primary, Katz, Matthew H.G., primary, Bauer, Todd W., primary, Nowak, Jonathan A., primary, Wolpin, Brian M., primary, Abrams, Thomas A., primary, Patel, Anuj, primary, Clancy, Thomas E., primary, Wang, Jiping, primary, Mancias, Joseph D., primary, Reilley, Matthew J., primary, Stucky, Chee-Chee H., primary, Bekaii-Saab, Tanios S., primary, Elias, Rawad, primary, Merchant, Nipun, primary, Slingluff, Craig L., primary, Rahma, Osama E., primary, and Dougan, Stephanie K., primary

Published
2024
Full Text
View/download PDF

45. Arm B count matrices 4 from PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with Pancreatic Cancer

Author

Ali, Lestat R., primary, Lenehan, Patrick J., primary, Cardot-Ruffino, Victoire, primary, Dias Costa, Andressa, primary, Katz, Matthew H.G., primary, Bauer, Todd W., primary, Nowak, Jonathan A., primary, Wolpin, Brian M., primary, Abrams, Thomas A., primary, Patel, Anuj, primary, Clancy, Thomas E., primary, Wang, Jiping, primary, Mancias, Joseph D., primary, Reilley, Matthew J., primary, Stucky, Chee-Chee H., primary, Bekaii-Saab, Tanios S., primary, Elias, Rawad, primary, Merchant, Nipun, primary, Slingluff, Craig L., primary, Rahma, Osama E., primary, and Dougan, Stephanie K., primary

Published
2024
Full Text
View/download PDF

46. Data from PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with Pancreatic Cancer

Author

Ali, Lestat R., primary, Lenehan, Patrick J., primary, Cardot-Ruffino, Victoire, primary, Dias Costa, Andressa, primary, Katz, Matthew H.G., primary, Bauer, Todd W., primary, Nowak, Jonathan A., primary, Wolpin, Brian M., primary, Abrams, Thomas A., primary, Patel, Anuj, primary, Clancy, Thomas E., primary, Wang, Jiping, primary, Mancias, Joseph D., primary, Reilley, Matthew J., primary, Stucky, Chee-Chee H., primary, Bekaii-Saab, Tanios S., primary, Elias, Rawad, primary, Merchant, Nipun, primary, Slingluff, Craig L., primary, Rahma, Osama E., primary, and Dougan, Stephanie K., primary

Published
2024
Full Text
View/download PDF

47. Supplementary Figure 1 from Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer

Author

Byrne, Katelyn T., primary, Betts, Courtney B., primary, Mick, Rosemarie, primary, Sivagnanam, Shamilene, primary, Bajor, David L., primary, Laheru, Daniel A., primary, Chiorean, E. Gabriela, primary, O'Hara, Mark H., primary, Liudahl, Shannon M., primary, Newcomb, Craig, primary, Alanio, Cécile, primary, Ferreira, Ana P., primary, Park, Byung S., primary, Ohtani, Takuya, primary, Huffman, Austin P., primary, Väyrynen, Sara A., primary, Dias Costa, Andressa, primary, Kaiser, Judith C., primary, Lacroix, Andreanne M., primary, Redlinger, Colleen, primary, Stern, Martin, primary, Nowak, Jonathan A., primary, Wherry, E. John, primary, Cheever, Martin A., primary, Wolpin, Brian M., primary, Furth, Emma E., primary, Jaffee, Elizabeth M., primary, Coussens, Lisa M., primary, and Vonderheide, Robert H., primary

Published
2024
Full Text
View/download PDF

48. Supplementary Figure 2 from Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer

Author

Byrne, Katelyn T., primary, Betts, Courtney B., primary, Mick, Rosemarie, primary, Sivagnanam, Shamilene, primary, Bajor, David L., primary, Laheru, Daniel A., primary, Chiorean, E. Gabriela, primary, O'Hara, Mark H., primary, Liudahl, Shannon M., primary, Newcomb, Craig, primary, Alanio, Cécile, primary, Ferreira, Ana P., primary, Park, Byung S., primary, Ohtani, Takuya, primary, Huffman, Austin P., primary, Väyrynen, Sara A., primary, Dias Costa, Andressa, primary, Kaiser, Judith C., primary, Lacroix, Andreanne M., primary, Redlinger, Colleen, primary, Stern, Martin, primary, Nowak, Jonathan A., primary, Wherry, E. John, primary, Cheever, Martin A., primary, Wolpin, Brian M., primary, Furth, Emma E., primary, Jaffee, Elizabeth M., primary, Coussens, Lisa M., primary, and Vonderheide, Robert H., primary

Published
2024
Full Text
View/download PDF

49. Supplementary Table 3 from Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer

Author

Byrne, Katelyn T., primary, Betts, Courtney B., primary, Mick, Rosemarie, primary, Sivagnanam, Shamilene, primary, Bajor, David L., primary, Laheru, Daniel A., primary, Chiorean, E. Gabriela, primary, O'Hara, Mark H., primary, Liudahl, Shannon M., primary, Newcomb, Craig, primary, Alanio, Cécile, primary, Ferreira, Ana P., primary, Park, Byung S., primary, Ohtani, Takuya, primary, Huffman, Austin P., primary, Väyrynen, Sara A., primary, Dias Costa, Andressa, primary, Kaiser, Judith C., primary, Lacroix, Andreanne M., primary, Redlinger, Colleen, primary, Stern, Martin, primary, Nowak, Jonathan A., primary, Wherry, E. John, primary, Cheever, Martin A., primary, Wolpin, Brian M., primary, Furth, Emma E., primary, Jaffee, Elizabeth M., primary, Coussens, Lisa M., primary, and Vonderheide, Robert H., primary

Published
2024
Full Text
View/download PDF

50. Supplementary Figure 3 from Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer

Author

Byrne, Katelyn T., primary, Betts, Courtney B., primary, Mick, Rosemarie, primary, Sivagnanam, Shamilene, primary, Bajor, David L., primary, Laheru, Daniel A., primary, Chiorean, E. Gabriela, primary, O'Hara, Mark H., primary, Liudahl, Shannon M., primary, Newcomb, Craig, primary, Alanio, Cécile, primary, Ferreira, Ana P., primary, Park, Byung S., primary, Ohtani, Takuya, primary, Huffman, Austin P., primary, Väyrynen, Sara A., primary, Dias Costa, Andressa, primary, Kaiser, Judith C., primary, Lacroix, Andreanne M., primary, Redlinger, Colleen, primary, Stern, Martin, primary, Nowak, Jonathan A., primary, Wherry, E. John, primary, Cheever, Martin A., primary, Wolpin, Brian M., primary, Furth, Emma E., primary, Jaffee, Elizabeth M., primary, Coussens, Lisa M., primary, and Vonderheide, Robert H., primary

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results